QN 019a
Alternative Names: QN-019aLatest Information Update: 28 Dec 2024
At a glance
- Originator Qihan Biotech
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported B-cell lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for phase-I development in B-cell lymphoma(Combination therapy, Second-line therapy or greater) in China (Parenteral)
- 28 Dec 2024 No recent reports of development identified for phase-I development in Precursor-B-cell-lymphoblastic-leukaemia-lymphoma(Monotherapy, Second-line therapy or greater) in China (Parenteral)
- 18 Jul 2023 National Medical Products Administration (NMPA) approves IND application for QN 019a in B-Cell Lymphoma in China